BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 28511060)

  • 1. A comparison study on RNase A oligomerization induced by cisplatin, carboplatin and oxaliplatin.
    Picone D; Donnarumma F; Ferraro G; Gotte G; Fagagnini A; Butera G; Donadelli M; Merlino A
    J Inorg Biochem; 2017 Aug; 173():105-112. PubMed ID: 28511060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platinated oligomers of bovine pancreatic ribonuclease: Structure and stability.
    Picone D; Donnarumma F; Ferraro G; Russo Krauss I; Fagagnini A; Gotte G; Merlino A
    J Inorg Biochem; 2015 May; 146():37-43. PubMed ID: 25756333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions of carboplatin and oxaliplatin with proteins: Insights from X-ray structures and mass spectrometry studies of their ribonuclease A adducts.
    Messori L; Marzo T; Merlino A
    J Inorg Biochem; 2015 Dec; 153():136-142. PubMed ID: 26239545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of cytotoxicities of platinum compounds.
    Goodisman J; Hagrman D; Tacka KA; Souid AK
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of oxaliplatin, cisplatin, and carboplatin with hemoglobin and the resulting release of a heme group.
    Mandal R; Kalke R; Li XF
    Chem Res Toxicol; 2004 Oct; 17(10):1391-7. PubMed ID: 15487901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of reaction of L-methionine with carboplatin and oxaliplatin in different media: a comparison with cisplatin.
    Heudi O; Mercier-Jobard S; Cailleux A; Allain P
    Biopharm Drug Dispos; 1999 Mar; 20(2):107-16. PubMed ID: 10206326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacology of platinum compounds: differences between the three molecules and factors of interpatient variability].
    Chatelut E
    Bull Cancer; 2011 Nov; 98(11):1253-61. PubMed ID: 22024542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. East-west fusion-necrosis and apoptosis acting in concert by demethylcantharidin-integrated platinum complexes.
    Pang SK; So WK; Ho YP; Au-Yeung CF
    Anticancer Agents Med Chem; 2014 Jun; 14(5):756-61. PubMed ID: 24476313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental study of renal disorder caused by oxaliplatin in rat renal cortical slices.
    Kanou T; Uozumi J; Soejima K; Tokuda Y; Masaki Z
    Clin Exp Nephrol; 2004 Dec; 8(4):310-5. PubMed ID: 15619029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and functional evaluation of interaction between mammalian ribosomal RNA with platinum-containing antineoplastic drugs.
    Theile D; Kos M
    Toxicol Lett; 2016 Feb; 242():47-52. PubMed ID: 26656794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Picoplatin binding to proteins: X-ray structures and mass spectrometry data on the adducts with lysozyme and ribonuclease A.
    Ferraro G; Lyčková T; Massai L; Štarha P; Messori L; Merlino A
    Dalton Trans; 2024 May; 53(20):8535-8540. PubMed ID: 38727007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Will the Interactions of Some Platinum (II)-Based Drugs with B-Vitamins Reduce Their Therapeutic Effect in Cancer Patients? Comparison of Chemotherapeutic Agents such as Cisplatin, Carboplatin and Oxaliplatin-A Review.
    Szefler B; Czeleń P
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly (γ, L-glutamic acid)-cisplatin bioconjugate exhibits potent antitumor activity with low toxicity: a comparative study with clinically used platinum derivatives.
    Feng Z; Lai Y; Ye H; Huang J; Xi XG; Wu Z
    Cancer Sci; 2010 Nov; 101(11):2476-82. PubMed ID: 20813014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Joint forces of mass spectrometric techniques (ICP-MS and MALDI-TOF-MS) and fluorescence spectrometry in the study of platinum-based cytostatic drugs interactions with metallothionein MT2 and MT3.
    Pavelicova K; Do T; Vejvodova M; Vaculovic T; Nowak K; Matczuk M; Wu S; Krężel A; Adam V; Vaculovicova M
    Talanta; 2024 Jul; 274():125920. PubMed ID: 38574532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modification of the physicochemical and pharmacological properties of anticancer platinum compounds by commercial 5-fluorouracil formulations: a comparative study using cisplatin and carboplatin.
    Fournier C; Hecquet B; Bastian G; Khayat D
    Cancer Chemother Pharmacol; 1992; 29(6):461-6. PubMed ID: 1568289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring binding affinity of oxaliplatin and carboplatin, to nucleoprotein structure of chromatin: spectroscopic study and histone proteins as a target.
    Soori H; Rabbani-Chadegani A; Davoodi J
    Eur J Med Chem; 2015 Jan; 89():844-50. PubMed ID: 25462284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin.
    Mohammed MQ; Retsas S
    Anticancer Drugs; 2000 Nov; 11(10):859-63. PubMed ID: 11142694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spontaneous translocation of antitumor oxaliplatin, its enantiomeric analogue, and Cisplatin from one strand to another in double-helical DNA.
    Malina J; Natile G; Brabec V
    Chemistry; 2013 Sep; 19(36):11984-91. PubMed ID: 23873652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin: mechanism of action and antineoplastic activity.
    Raymond E; Faivre S; Woynarowski JM; Chaney SG
    Semin Oncol; 1998 Apr; 25(2 Suppl 5):4-12. PubMed ID: 9609103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboplatin and oxaliplatin decomposition in chloride medium, monitored by XAS.
    Curis E; Provost K; Bouvet D; Nicolis I; Crauste-Manciet S; Brossard D; Bénazeth S
    J Synchrotron Radiat; 2001 Mar; 8(Pt 2):716-8. PubMed ID: 11512906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.